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1. Genetics' 
~ Genotype-phenotype characteristics in Cystic Fibrosis - study on 
20 children with Cystic Fibrosis in Romania 
S. Mosescu, E.R Ciofu. Clinical Central Children ~' Hospital, Bucharest, Romania 
Aims: establish the incidence of AF508 mutation and to find out genotype pheno- 
type correlation, on a group of 20 children with cystic fibrosis(CF), diagnosed and 
treated in Central Children's Hospital, Bucharest. 
Methods: We studied 20 children with CE Positive diagnosis was based on clinical 
findings, sweat test (Wescor) and genetic mutation determination (PCR). They 
were analyzed for: age diagnosis, severity of respiratory disease, bronchiectasis 
under 2 years old, meconium ileus, steatorrhoea, nutritional failure and capacity 
to catch up growth, hypoproteinemic edema, hyponatremic seizures, hypocholes- 
terolemia, chronic metabolic severe alkalosis, rectal prolapse and genetic mutation. 
Results: AF508 mutation was present in 65% of the children; homozygous AF508 
were 30%. Nutritional failure presented in 75% and all homozygous had failure 
to thrive and steatorrhoea. The capacity to catch up growth for homozygous was 
as good as for non-AF508. Bronchiectasis was present under 2 years old for 35%, 
and 75% of these had AF508 mutation. Clinical score and radiographic pulmonary 
changes were more severe in children with AF508. Meconium ileus had 15%. 
Hypoproteinemic edema had 20%. 2 children had rectal prolapse (both AF508). 
Hyponatremic seizures presented in 20%. Severe chronic metabolic alkalosis had 
20 (all of them with AF508 mutation). 
Conclusions: This study shows an incidence of AF508 mutation of 65%, different 
from the study made in Romania in 1997 that found 28.5%, but similar with a study 
on 165 Romanian CF children (2005) which found an incidence of 60.55%. In our 
study AF508 was correlated with: nutritional failure, steatorrhoea, bronchiectasis 
at younger ages, severity of pulmonary disease, rectal prolapse, hypoproteinemia, 
edema, hyponatriemia, hypocholesterolemia and chronic metabolic alkalosis. 
$3 
1~ Complete molecular analysis of the CFTR gene in congenital 
absence of the vas deferens 
A. Grangeia 1 , F. Carvalho 1 , E. Girodon 2, J. Silva 3, M. Sousa 1'3'4, A. Barros 1'3. 
1Dept. Genetics, Faculty of Medicine, University of Porto, Portugal; 2Dept 
Biochem Genetics, Henri Mondor Hospital C?eteil, France; 3 Centre Reproductive 
Genetics ABarros, 4Lab Cell Biology, ICBAS, University of Porto, Portugal 
Aim: To determine CFTR gene involvement in CAVD patients. 
Methods: 46 patients with isolated CAVD and 8 with CAVD and renal malfor- 
mations were first screened for the 31 most frequent CF mutations. An extensive 
CFTR screening was performed by DGGE and dHPLC. CFTR gene rearrangements 
were searched by semi-quantitative fluorescent multiplex PCR (QFM-PCR). Poly-T 
variants of intron 8 (1342 6(T)5-9) were studied by fluorescent PCR. Poly-TG at 
1342 12(TG)9-13 was analysed by DGGE. 
Results: 35 CF mutations were initially identified in 31 patients (67.4%) with 
isolated CAVD. DGGE/dHPLC detected 29 further mutations, of which 4 have not 
been previously reported. Three of these novel mutations are pathogenic, as con- 
firmed by expression analysis. QFM-PCR detected a large deletion in a patient and 
the homozygous status for a mutation was confirmed in two others. The 5T variant 
was found in 28 alleles (30.4%). With this extensive screening, the number of cases 
with at least one CFTR mutation increased to 44 (95.7%): 39 (84.8%) with two 
mutations and 5 (10.9%) with one. The compound heterozygosity of the 5T variant 
and a CF or CFTR mutation accounted for 20/39 (51.3%) of the total known 
genotypes. Among the patients with renal malformations, only one CFTR mutation 
was found in one patient, this one being novel. 
Conclusions: About 20% of CAVD patients without renal malformations remain 
without molecular diagnosis. Here we show that an extensive CFTR gene analysis 
of CAVD patients enables to increase the mutation detection rate to about 96%. 
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[ ] C y s t i c  Fibrosis: genetic-clinical correlation 
C. Gonz~lez 1 , I. Largo 12, j. Lozano 2. 1 Universidad de Chile, 2Hospital Roberto del 
Rio, Santiago, Chile 
61 patients, 23 women (38%), mean age 1 year (y) and 6 months (too), at diagnosis 
9y and 9too. Genetic study in 32 for 32 mutations (M) and in 12 for 965, genetic and 
clinical were related. 
i. 40 patients without M: 
24 (60%) pancreatic insufficiency (PI), mean: 15 y, at diagnosis 9 y 5 too; Sodium 
74,Chlorine 72, Shwachman 69. Record: 92% repetitive obstructive bronchial syn- 
drome (ROBS), 71% bronchopneumonia, 50% malnutrition, today 54% eutrophic, 
50% bronchial cultures ( ) ,  FEV1 82%, 63% pansinusitis. 
16 (40%) pancreatic sufficient (PS); mean: 13yl l  too, at diagnosis 10yl too; 
Sodium 72, Chlorine 51, Shwachman 76. Record: 81% ROBS, 44% bronchop- 
neumonia, 31% malnutrition, today 44% eutrophic, 88% bronchial cultures ( ) ,  
FEV1 91%, 56% pansinusitis. 
ii. 8 patients with AF508 in 1 or 2 alleles: 
6 (75%) PI; mean: 12y6mo, at diagnosis 2y4mo; Sodium 95, Chlorine 102, 
Shwachman 60. Record: 100% ROBS, 67% bronchopneumonia, 75% malnutri- 
tion, today 17% eutrophic, 83% overweight, 17% bronchial cultures ( ) ,  FEV1 
78%, 71% pansinusitis. 
2 (25%) PS; mean: 13yl l  too, at diagnosis 10y7mo; Sodium 67, Chlorine 72, 
Shwachman 65. Record: 100% ROBS, 50% bronchopneumonia, 50% malnutri- 
tion, today 50% eutrophic, 50% at risk, 0% bronchial cultures ( ) ,  FEV1 59%, 
100% pansinusitis. 
iii. 13 patients with MfM other than AF508: 
7 (54%) IP; mean: 13y2 too, at diagnosis 7y 1 too, Sodium 92, Chlorine 86, 
Shwachman 67. Record: 100% ROBS, 86% bronchopneumonia, 14% malnutri- 
tion, today 71% eutrophic, 29% at risk, 14% bronchial cultures ( ) ,  FEV1 90%, 
71% pansinusitis. 
2 (25%) PS; mean: 11 y, at diagnosis 9 y 7 too; Sodium 43, Chlorine 31, Shwach- 
man 64. Record: 67% ROBS, 67% bronchopneumonia, 0% malnutrition, today 
0% eutrophic, 17% at risk, 17% malnutrition, 33% bronchial cultures ( ) ,  FEV1 
66%, 67% pansinusitis. 
Conclusions: The diagnosis age of our patients is very delayed, which makes in- 
dispensable the screening in newborn. CF disease is worst in AF508, with the earliest 
diagnosis. All groups have common symptoms. Probably the genetics in our population 
differs from that found in other ethnic groups. 
1 •  Rapid and reliable analysis of the CFTR locus in CBAVD patients 
M. des Georges, C. Guittard, J.R Alti~ri, C. Templin, C. Bareil, M. Claustres. 
Laboratoire de Gdndtique Moldculaire, CHU, Montpellier, France 
Congenital bilateral absence of the vas deferens (CBAVD) is a genital form of 
cystic fibrosis (CF). An extensive CFTR scanning was carried out in 180 Southern 
France CBAVD males by DGGE or DHPLC (abnormally migrating fragments 
were characterized bysequencing) and completed by 3 semi-quantitative fluorescent 
PCRs to detect large rearrangements. 85 different mutations were identified showing 
an extreme alMic heterogeneity: 2 large deletions and 83 point mutations spanning 
23 exonic and 11 intronic regions. 40% are not detected by commercial kits. The 
two major mutations were: p.F508del (23.3%) and the partially penetrant T5 variant 
in IVS8 (15.5%) which is influenced by the number of adjacent TG repeats not 
identified by kits. 
To improve fficiency of current scanning methods, we developed irect sequence 
analysis of the entire coding region of the CFTR gene in single condition reaction: 
we analysed the 27 exons and flanking sequences in 30 amplicons (analysis on 
ABI 3130xl/Seqscape software). We also developed fluorescent assay to haplotype 
the (TG)mTn complex allele using 3 PCRs: Tn, (TG)m and both (TG)mTn (analysis 
on ABI 310 or 3130xl/Genescan software). 
These two analyses can be routinely performed within three working days and allow 
an easy detection of all point mutations and short deletions as well as the (TG)mTn 
haplotyping. These two simple, rapid and reliable assays are methods of choice for 
mutation screening in CBAVD patients. The single condition sequencing strategy of 
the entire coding region and flanking sequences is also recommended in CF patients 
when frequent mutations are not found, in partners of CF patients, and in fetuses 
with hyperechogenic bowel and heterozygous for one frequent CFTR mutation. 
